=============================================================== == == == ----------- ALS INTEREST GROUP ----------- == == ALS Digest (#52, 25 JULY 1993) == == == == To subscribe, to unsubscribe, to contribute notes, == == etc. to ALS Digest, please send e-mail to: == == bro@huey.met.fsu.edu (Bob Broedel) == == == == All interested people may "broadcast" messages to == == ALS Digest subscribers by sending to: == == als@huey.met.fsu.edu == == == =============================================================== (1) ===== building the ALS e-mail network ========== Date : Wed, 21 Jul 93 19:52:09 -0700 >From : geobob@scripps.edu (George Siggins) Subject: ALS Interest Group I am indeed interested in hearing news about ALS research. Our group studies the electrophysiology and some micro-anatomy of drug action (ethanol, opiates, others) but we are also now embarking on studies of Alzheimer's (e.g., beta amyloid effects) and virus (HIV, FIV, LCMV) effects on brain neurons in vivo and vitro. We are also involved in research on the function of acetylcholine, excitatory amino acids, and somatostatin, and synaptic physiology in general. George Robert Siggins (geobob@scripps.edu) Dept. Neuropharmacology, 10666 N. Torrey Pines Rd. The Scripps Research Institute Research Institute, La Jolla CA 92037 (2) ===== RILUZOLE ========== The most recent edition of the ALS Association's DRUG TRIALS FOR ALS PATIENTS (revised 06/25/93) includes information about clinical trials of the drug Riluzole, which has an inhibitory effect on glutamate. Here is the result of a preliminary search for information about the drug. Please be sure to look at heading #15. ----- Pharmacology scan results for: RILUZOLE PRESS TO SEARCH Results Format Source Type Drug Information Fulltext 0 full text handbook Int'l Pharmaceutical Abstracts 0 abstract journals Pharmaceutical News Index...........5 reference multiple sources SciSearch (1974-to date)...........19 reference journals Trade & Industry Index 0 reference multiple sources ADIS DrugNews.......................1 abstract multiple sources BioBusiness 0 reference journals Pharmline 0 abstract journals System is now searching the SciSearch database, copyrighted 1993 by the Institute for Scientific Information, Philadelphia, PA, and available through Dialog Information Services, Inc. Heading # 1 Title: OPTICAL ISOMERS OF RP 64406 - NEW POTENT ANTIGLUTAMATE AGENTS Author(s): JIMONET P; BEAUDOIN F; CHEVE M; DUCROTOY G; DUTRUCROSSET G; LURIER D; RATAUD J; STUTZMANN JM; MIGNANI S Corporate Source: RHONE POULENC RORER,CENT RES,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE/F-94403 VITRY//FRANCE/ Journal: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, V3, N6 (JUN), P 983-988 Heading # 2 Title: INHIBITION BY *RILUZOLE* OF ELECTROPHYSIOLOGICAL RESPONSES MEDIATED BY RAT KAINATE AND NMDA RECEPTORS EXPRESSED IN XENOPUS-OOCYTES Author(s): DEBONO MW; LEGUERN J; CANTON T; DOBLE A; PRADIER L Corporate Source: CTR RECH VITRY ALFORVILLE,RHONE POULENC RORER,DEPT BIOL,13 QUAI JULES GUESDE,BP 14/F-94403 VITRY//FRANCE/ Journal: EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, V235, N2-3 (APR 28), P 283-289 Heading # 3 Title: FAST K-CHANNELS ARE MORE SENSITIVE TO *RILUZOLE* THAN SLOW K-CHANNELS IN MYELINATED NERVE-FIBER Author(s): BENOIT E; ESCANDE D Corporate Source: UNIV PARIS 11,PHYSIOL CELLULAIRE LAB,CNRS,URA 1121,BAT 443/F-91405 ORSAY//FRANCE/ Journal: PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1993, V422, N5 ( FEB), P536-538 Heading # 4 Title: EFFECT OF *RILUZOLE* ON FOCAL CEREBRAL-ISCHEMIA IN RATS Author(s): WAHL F; ALLIX M; PLOTKINE M; BOULU RG Corporate Source: UNIV PARIS 05,FAC SCI PHARMACEUT & BIOL,PHARMACOL LAB,4 AVE OBSERV/F-75270 PARIS 06//FRANCE/ Journal: EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, V230, N2 (JAN 12), P 209-214 Heading # 5 Title: *RILUZOLE* INHIBITS THE RELEASE OF GLUTAMATE IN THE CAUDATE-NUCLEUS OF THE CAT INVIVO Author(s): CHERAMY A; BARBEITO L; GODEHEU G; GLOWINSKI J Corporate Source: COLL FRANCE,INSERM,U114,CHAIRE NEUROPHARMACOL/F-75231 PARIS 05//FRANCE/; COLL FRANCE,INSERM,U114,CHAIRE NEUROPHARMACOL/F-75231 PARIS 05//FRANCE/ Journal: NEUROSCIENCE LETTERS, 1992, V147, N2 (DEC 7), P209-212 Heading # 6 Title: VERSATILE METHODS FOR THE SYNTHESIS OF 2-AMINO-6-TRIFLUOROMETHOXY-(NITRO)BENZOTHIAZOLES Author(s): MIGNANI S; AUDIAU F; LEBLEVEC J; NEMECEK C; BARREAU M; JIMONET P ; GUEREMY C Corporate Source: RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE,BP14/F-94403 VITRY//FRANCE/ Journal: SYNTHETIC COMMUNICATIONS, 1992, V22, N19, P2769-2780 Heading # 7 Title: PERTUSSIS TOXIN PRETREATMENT ABOLISHES THE INHIBITORY EFFECT OF *RILUZOLE* AND CARBACHOL ON D-[H-3]ASPARTATE RELEASE FROM CULTURED CEREBELLAR GRANULE CELLS Author(s): DOBLE A; HUBERT JP; BLANCHARD JC Corporate Source: RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,DEPT BIOL,13 QUAI JULES GUESDE/F-94403 VITRY//FRANCE/ Journal: NEUROSCIENCE LETTERS, 1992, V140, N2 (JUN 22), P251-254 Heading # 8 Title: NEUROPROTECTIVE ACTIONS OF *RILUZOLE* IN RODENT MODELS OF GLOBAL AND FOCAL CEREBRAL-ISCHEMIA Author(s): PRATT J; RATAUD J; BARDOT F; ROUX M; BLANCHARD JC; LADURON PM; STUTZMANN JM Corporate Source: RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,DEPT BIOL,13 QUAI J GUESDE/F-94403 VITRY//FRANCE/ Journal: NEUROSCIENCE LETTERS, 1992, V140, N2 (JUN 22), P225-230 Heading # 9 Title: EFFECTS OF *RILUZOLE* (2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE) ON STRIATAL NEUROCHEMICAL MARKERS IN THE RAT, WITH SPECIAL REFERENCE TO THE DOPAMINE, CHOLINE, GABA AND GLUTAMATE SYNAPTOSOMAL HIGH-AFFINITY UPTAKE SYSTEMS Author(s): SAMUEL D; BLIN O; DUSTICIER N; NIEOULLON A Corporate Source: CNRS,NEUROBIOL CELLULAIRE & FONCTIONNELLE LAB,31 CHEMIN JOSEPH AIGUIER/F-13402 MARSEILLE 9//FRANCE/; CHU TIMONE/F-13385 MARSEILLE//FRANCE/ Journal: FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1992, V6, N4-5, P177-184 Heading # 10 Title: ANESTHETIC PROPERTIES OF *RILUZOLE* (54274-RP), A NEW INHIBITOR OF GLUTAMATE NEUROTRANSMISSION Author(s): MANTZ J; CHERAMY A; THIERRY AM; GLOWINSKI J; DESMONTS JM Corporate Source: HOP BICHAT,DEPT ANESTHESIOL,46 RUE HENRI HUCHARD/F-75877 PARIS 18//FRANCE/; COLL FRANCE,DEPT NEUROPHARMACOL,INSERM,U114/F-75231 PARIS 05//FRANCE/ Journal: ANESTHESIOLOGY, 1992, V76, N5 (MAY), P844-848 Heading # 11 Title: *RILUZOLE* SPECIFICALLY BLOCKS INACTIVATED NA CHANNELS IN MYELINATED NERVE-FIBER Author(s): BENOIT E; ESCANDE D Corporate Source: UNIV PARIS 11,PHYSIOL COMPAREE LAB,CNRS,URA 1121,BAT 443/F-91405 ORSAY//FRANCE/; RHONE POULENC RORER,CTR RECH VITRY/F-94403 VITRY//FRANCE/ Journal: PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1991, V419, N6 ( DEC), P603-609 Heading # 12 Title: USE OF A CONFLICT PROCEDURE IN PIGEONS TO CHARACTERIZE ANXIOLYTIC DRUG ACTIVITY - EVALUATION OF N-METHYL-D-ASPARTATE ANTAGONISTS Author(s): KOEK W; COLPAERT FC Corporate Source: CTR RECH PIERRE FABRE,17 AVE JEAN MOULIN/F-81106 CASTRES//FRANCE/; FONDAX,GRP RECH SERVIER,DIV NEUROBIOL/F-92800 PUTEAUX//FRANCE/ Journal: LIFE SCIENCES, 1991, V49, N9, PPL37-PL42 Heading # 13 Title: ANTICONVULSANT AND SLEEP-WAKING INFLUENCES OF *RILUZOLE* IN A RAT MODEL OF ABSENCE EPILEPSY Author(s): ROMETTINO S; LAZDUNSKI M; GOTTESMANN C Corporate Source: UNIV NICE,FAC SCI,PSYCHOPHYSIOL LAB,PARC VALROSE/F-06034 NICE//FRANCE/; UNIV NICE,FAC SCI,PSYCHOPHYSIOL LAB,PARC VALROSE/F-06034 NICE//FRANCE/ Journal: EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, V199, N3, P371-373 Heading # 14 Title: EFFECTS OF NMDA RECEPTOR ANTAGONISTS AND SIGMA-LIGANDS ON THE ACQUISITION OF CONDITIONED FEAR IN MICE Author(s): SANGER DJ; JOLY D Corporate Source: SYNTHELABO RECH,31 AVE PV COUTURIER/F-92220 BAGNEUX//FRANCE/ Journal: PSYCHOPHARMACOLOGY, 1991, V104, N1, P27-34 Heading # 15 Title: IS *RILUZOLE* A GLUTAMATE ANTAGONIST Author(s): HAYS SJ; SCHWARZ RD; COUGHENOUR LL; BOYD DK; ANDERSON RJ; BOXER PA Corporate Source: WARNER LAMBERT PARKE DAVIS,DIV PHARMACEUT RES/ANN ARBOR//MI/48105 Journal: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, V201, APR, P14-MEDI Language: ENGLISH Document Type: MEETING ABSTRACT Heading # 16 Title: *RILUZOLE* PREVENTS HYPEREXCITABILITY PRODUCED BY THE MAST-CELL DEGRANULATING PEPTIDE AND DENDROTOXIN-I IN THE RAT Author(s): STUTZMANN JM; BOHME GA; GANDOLFO G; GOTTESMANN C; LAFFORGUE J; BLANCHARD JC; LADURON PM; LAZDUNSKI M Corporate Source: RHONE POULENC SANTE,CTR RECH VITRY,UNITE ELECTROPHYSIOL/F-94403 VITRY//FRANCE/; FAC SCI NICE,PSYCHOPHYSIOL LAB/F-06034 NICE//FRANCE/; CNRS,CTR BIOCHIM/F-06031 NICE//FRANCE/ Journal: EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, V193, N2, P223-229 Heading # 17 Title: *RILUZOLE*, A NOVEL ANTIGLUTAMATE, PREVENTS MEMORY LOSS AND HIPPOCAMPAL NEURONAL DAMAGE IN ISCHEMIC GERBILS Author(s): MALGOURIS C; BARDOT F; DANIEL M; PELLIS F; RATAUD J; UZAN A; BLANCHARD JC; LADURON PM Corporate Source: RHONE POULENC SANTE,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE,BP 14/F-94403 VITRY//FRANCE/; RHONE POULENC SANTE,CTR RECH GENNEVILLIERS/F-92231 GENNEVILLIERS//FRANCE/ Journal: JOURNAL OF NEUROSCIENCE, 1989, V9, N11, P3720-3727 Heading # 18 Title: *RILUZOLE* ANTAGONIZES THE ANXIOGENIC PROPERTIES OF THE BETA-CARBOLINE FG-7142 IN RATS Author(s): STUTZMANN JM; CINTRAT P; LADURON PM; BLANCHARD JC Corporate Source: RHONE POULENC SANTE,CTR RECH VITRY,13 QUAI JULES GUESDE/F-94403 VITRY//FRANCE/ Journal: PSYCHOPHARMACOLOGY, 1989, V99, N4, P515-519 Heading # 19 Title: *RILUZOLE*, A GLUTAMATE ANTAGONIST, ENHANCES SLOW-WAVE AND REM-SLEEP IN RATS Author(s): STUTZMANN JM; LUCAS M; BLANCHARD JC; LADURON PM Corporate Source: CTR RECH VITRY,RHONE POULENC SANTE,13 QUAI J GUESDE/F-94403 VITRY SUR SEINE//FRANCE/ Journal: NEUROSCIENCE LETTERS, 1988, V88, N2, P195-200 (3) ===== BDNF ========== OTC 07/21 1024 Regeneron receives second US patent on BDNF TARRYTOWN, N.Y. (JULY 21) BUSINESS WIRE - Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced Wednesday that it has received a second U.S. patent (No. 5,229,500) on brain-derived neurotrophic factor (BDNF). The second patent, which covers compositions containing the BDNF protein, was issued to Max Planck Institute and Regeneron, which is the exclusive worldwide licensee of this technology from the Max Planck Institute. Paul Lubetkin, vice president, general counsel, and secretary of Regeneron, said, "This patent, together with our previously issued patent to the BDNF gene, further strengthens Regeneron's intellectual property position in connection with this technology. Regeneron is developing BDNF with Amgen Inc., and the companies announced on July 19 that an Investigational New Drug (IND) application was submitted to the United States Food and Drug Administration for a clinical study of the safety and potential efficacy of BDNF to treat amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease), an inevitably fatal disease of motor neurons." Regeneron is a leader in the discovery and development of biotechnology-based compounds focused on the treatment of neurodegenerative diseases, peripheral neuropathies and nerve injuries, including such conditions as Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease and spinal cord injuries. CONTACT: Regeneron Pharmaceuticals Inc., Tarrytown Fredric D. Price, 914/347-7000 (4) ===== Lorenzo's Oil ========== A video of the film Lorenzo's Oil has just been released. == end of als 52 ==